Prudent Drug Discovery Company
Low market cap ( appox £13m at time of writing ).
Issues shares very rarely ( last placing nearly four years ago ).
Has material interest in its work from larger partners ( Pharmaxis ).
Sold interest in LOXL2 programme for £5m to Pharmaxis in December.
Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains...
Fundamentally sound business but CEO's recent interview makes the short-term wins (like the IPPC permit) sound less imminent so will probably see some people trade out before coming back later. Therefore expect another visit down to bottom of channel before bouncing and then potentially breaking top out of downward wedge.